A method for damaging viruses in a human tissue comprised generating a series of ultra-short pulse laser (USPL) pulses by a USPL generator, radiating the USPL pulses by a USPL applicator and exposing the human tissue to a defined number of generated USPL pulses wherein an energy absorbing enhancing substance is disposed between the human tissue and the USPL applicator.

An embodiment provides a method for treating a body fluid of a patient with Covid-19, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a virion in the body fluid to form an antibody-virion complex, wherein the antibody comprises a tag sensitive to an illumination; removing the antibody-virion complex from the body fluid using an illumination source; and returning the body fluid to the patient. Other aspects are described and claimed.

A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

A method for prophylaxis or treatment of a graft's rejection of a recipient, driven and adjusted by a microprocessor-based controller. Provided is a fluid circuit comprising a first container configured to receive a transplant component and a second container configured to receive an apoptotic component. Provided is a separator configured to associate with the fluid circuit and separate whole blood into a red blood cell component, a plasma component, and a white blood cell component. Whole blood is directed into the fluid circuit and the separator. The whole blood is separated into the red blood cell component, the plasma component, and the white blood cell component. A first portion comprising the transplant component of the white blood cell component is directed to the first container. A second portion of the white blood cell component is directed to the second container and the second portion is rendered apoptotic.

Methods and systems for sampling blood components in a photopheresis procedure are disclosed. The methods include collecting samples at selected times during a photopheresis procedure.

Mid-procedure termination of a mononuclear cell collection procedure may prevent collection of an amount of red blood cells that is required to harvest a complete mononuclear cell product. Blood separation systems and methods are provided for minimizing the impact of or recovering from mid-procedure termination of such a mononuclear cell collection procedure. According to one approach, blood or separated red blood cells are conveyed into a red blood cell collection container relatively early in the procedure to minimize the impact of a later termination of the procedure. According to another approach, blood and/or separated red blood cells within a fluid processing assembly are redirected through the fluid processing assembly following mid-procedure termination to allow for at least partial mononuclear cell collection. According to yet another approach, a double-needle fluid processing assembly may be converted into a single-needle configuration to allow for continued processing following mid-procedure termination.

Systems and methods for performing online extracorporeal photopheresis of mononuclear cells are disclosed. Whole blood is removed from a patient and introduced through a processing set into a separation chamber to separate the desired cell population from the blood. The separated cell population is processed through the set which is associated with a treatment chamber where the cells are treated. Once treated, the cells are returned to the patient. The processing set remains connected to the patient during the entire ECP treatment procedure and provides an online, sterile closed pathway between the separation chamber and the treatment chamber.

Provided are methods for preparing pathogen-inactivated platelet compositions, as well as processing sets and compositions related thereto.

An ultraviolet irradiation (UBI) device is configured to simultaneously irradiate blood flowing through a flat quartz crystal cuvette with both UV-A and UV-C light, wherein UV-A and UV-C lamps are positioned on opposite sides of the cuvette and calibrated to produce a two point source interference pattern having constructive interference points and maximum light intensity within the flow-through cuvette. Treatment of a cancer, an infectious disease or an autoimmune disease in a patient comprises simultaneously irradiating the blood with UV-A and UV-C light as it flows through the cuvette of the UBI device and into the vasculature of the patient.

A system, device, and autologous method for treating blood. Blood is extracted from a patient. The blood is tested to determine one or more pathogens and conditions of the blood. One or more catalysts are automatically added into the blood of the patient. The one or more catalysts are activated utilizing the one or more emitters configured to interact with the one or more catalysts in the blood create treated blood. One or more additives are added into the threated blood. The treated blood is reinjected into the patient.